These inhibitors have demonstrated efficacy in a broad spectrum of acute myeloid leukemias, and mice and human PDX AML models, suggesting their potential effectiveness in CML blast crisis and TKI-resistant cells, where METTL3 knockdown exhibits a robust antiproliferative effect [25]. Here, METTL3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.